RPG Life Sciences Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: July 4, 2025, 11:06 pm

Market Cap	4,158 Cr.
Current Price	2,520
High / Low	2,977/1,540
Stock P/E	36.0
Book Value	321
Dividend Yield	0.79 %
ROCE	32.8 %
ROE	25.5 %
Face Value	8.00
PEG Ratio	1.01

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for RPG Life Sciences Ltd

Competitors of RPG Life Sciences Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	141 Cr.	100	247/84.3	27.3	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.48 Cr.	2.87	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	38.7 Cr.	52.2	94.9/45.2		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	36.3 Cr.	24.8	29.1/13.1	35.6	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	19,093.44 Cr	1,196.96		103.53	194.43	0.30%	16.64%	15.18%	6.18

All Competitor Stocks of RPG Life Sciences Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	104	129	135	131	118	148	154	154	127	165	172	173	143
Expenses	90	101	105	101	103	116	116	116	106	126	126	124	118
Operating Profit	14	28	30	29	16	32	37	38	21	39	46	49	25
OPM %	13%	22%	22%	22%	13%	22%	24%	25%	16%	24%	27%	28%	18%
Other Income	1	1	1	1	2	2	2	2	2	2	-25	3	115
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	4	4	4	4	4	4	4	4	4	5	5	5	5
Profit before tax	11	25	27	26	14	30	35	36	18	36	15	47	135
Tax %	31%	28%	26%	26%	25%	26%	26%	26%	25%	26%	72%	26%	13%
Net Profit	8	18	20	19	10	22	26	26	13	27	4	35	117
EPS in Rs	4.55	11.01	12.07	11.55	6.26	13.36	15.64	16.00	8.01	16.18	2.54	21.12	70.95

Last Updated: May 31, 2025, 7:56 am

Below is a detailed analysis of the quarterly data for RPG Life Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 143.00 Cr.. The value appears to be declining and may need further review. It has decreased from 173.00 Cr. (Dec 2024) to 143.00 Cr., marking a decrease of 30.00 Cr..
For Expenses, as of Mar 2025, the value is 118.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 124.00 Cr. (Dec 2024) to 118.00 Cr., marking a decrease of 6.00 Cr..
For Operating Profit, as of Mar 2025, the value is 25.00 Cr.. The value appears to be declining and may need further review. It has decreased from 49.00 Cr. (Dec 2024) to 25.00 Cr., marking a decrease of 24.00 Cr..
For OPM %, as of Mar 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 28.00% (Dec 2024) to 18.00%, marking a decrease of 10.00%.
For Other Income, as of Mar 2025, the value is 115.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Dec 2024) to 115.00 Cr., marking an increase of 112.00 Cr..
For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
For Depreciation, as of Mar 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 5.00 Cr..
For Profit before tax, as of Mar 2025, the value is 135.00 Cr.. The value appears strong and on an upward trend. It has increased from 47.00 Cr. (Dec 2024) to 135.00 Cr., marking an increase of 88.00 Cr..
For Tax %, as of Mar 2025, the value is 13.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Dec 2024) to 13.00%, marking a decrease of 13.00%.
For Net Profit, as of Mar 2025, the value is 117.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Dec 2024) to 117.00 Cr., marking an increase of 82.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 70.95. The value appears strong and on an upward trend. It has increased from 21.12 (Dec 2024) to 70.95, marking an increase of 49.83.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:17 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	236	242	279	294	344	330	376	389	440	513	582	653
Expenses	224	228	256	274	306	296	315	318	353	408	453	494
Operating Profit	12	14	23	20	38	34	60	71	87	104	129	160
OPM %	5%	6%	8%	7%	11%	10%	16%	18%	20%	20%	22%	24%
Other Income	66	1	1	18	1	1	-5	1	3	4	7	95
Interest	3	3	2	4	5	5	3	2	1	1	1	1
Depreciation	11	11	10	11	14	15	16	16	16	16	17	21
Profit before tax	65	1	12	23	20	15	36	54	73	92	118	233
Tax %	18%	-0%	-0%	10%	34%	28%	20%	25%	30%	26%	26%	21%
Net Profit	53	1	12	21	13	11	29	40	51	68	88	183
EPS in Rs	32.29	0.60	7.03	12.70	8.13	6.54	17.54	24.19	31.13	40.90	53.00	110.79
Dividend Payout %	6%	132%	23%	22%	30%	37%	23%	30%	31%	29%	30%	22%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	-98.11%	1100.00%	75.00%	-38.10%	-15.38%	163.64%	37.93%	27.50%	33.33%	29.41%	107.95%
Change in YoY Net Profit Growth (%)	0.00%	1198.11%	-1025.00%	-113.10%	22.71%	179.02%	-125.71%	-10.43%	5.83%	-3.92%	78.54%

RPG Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	10%
5 Years:	12%
3 Years:	14%
TTM:	12%

Compounded Profit Growth
10 Years:	63%
5 Years:	29%
3 Years:	31%
TTM:	33%

Stock Price CAGR
10 Years:	30%
5 Years:	57%
3 Years:	66%
1 Year:	55%

Return on Equity
10 Years:	20%
5 Years:	24%
3 Years:	25%
Last Year:	26%

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:26 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	13	13	13	13	13	13	13	13	13	13	13	13
Reserves	113	112	120	134	142	147	163	203	243	294	362	517
Borrowings	15	33	23	45	54	36	12	2	1	0	-0	-0
Other Liabilities	56	39	49	55	82	54	78	85	88	112	138	127
Total Liabilities	196	197	205	247	291	251	267	303	345	419	513	658
Fixed Assets	106	105	109	137	131	128	123	113	104	124	114	184
CWIP	1	1	2	2	9	17	10	12	31	25	96	4
Investments	-0	-0	-0	-0	-0	-0	-0	-0	-0	58	91	127
Other Assets	89	92	94	108	152	106	134	178	210	211	212	343
Total Assets	196	197	205	247	291	251	267	303	345	419	513	658

Below is a detailed analysis of the balance sheet data for RPG Life Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
For Reserves, as of Mar 2025, the value is 517.00 Cr.. The value appears strong and on an upward trend. It has increased from 362.00 Cr. (Mar 2024) to 517.00 Cr., marking an increase of 155.00 Cr..
For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 127.00 Cr.. The value appears to be improving (decreasing). It has decreased from 138.00 Cr. (Mar 2024) to 127.00 Cr., marking a decrease of 11.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 658.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 513.00 Cr. (Mar 2024) to 658.00 Cr., marking an increase of 145.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 184.00 Cr.. The value appears strong and on an upward trend. It has increased from 114.00 Cr. (Mar 2024) to 184.00 Cr., marking an increase of 70.00 Cr..
For CWIP, as of Mar 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 96.00 Cr. (Mar 2024) to 4.00 Cr., marking a decrease of 92.00 Cr..
For Investments, as of Mar 2025, the value is 127.00 Cr.. The value appears strong and on an upward trend. It has increased from 91.00 Cr. (Mar 2024) to 127.00 Cr., marking an increase of 36.00 Cr..
For Other Assets, as of Mar 2025, the value is 343.00 Cr.. The value appears strong and on an upward trend. It has increased from 212.00 Cr. (Mar 2024) to 343.00 Cr., marking an increase of 131.00 Cr..
For Total Assets, as of Mar 2025, the value is 658.00 Cr.. The value appears strong and on an upward trend. It has increased from 513.00 Cr. (Mar 2024) to 658.00 Cr., marking an increase of 145.00 Cr..

Notably, the Reserves (517.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	-6	-2	33	7	15	46	50	58	65	91	94	78
Cash from Investing Activity +	59	-10	-15	-30	-16	-19	-11	-8	-35	-106	-79	-42
Cash from Financing Activity +	-54	12	-18	23	0	-26	-39	-10	-14	-17	-20	-27
Net Cash Flow	0	-0	-0	1	-1	0	0	40	17	-32	-5	9

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-3.00	-19.00	0.00	-25.00	-16.00	-2.00	48.00	69.00	86.00	104.00	129.00	160.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	81	56	61	48	49	72	43	62	54	27	27	31
Inventory Days	140	180	149	156	163	171	136	133	162	214	203	200
Days Payable	226	176	109	135	102	165	83	127	132	117	138	140
Cash Conversion Cycle	-5	60	101	70	110	78	96	68	84	124	91	90
Working Capital Days	46	51	76	54	50	62	53	46	53	47	33	25
ROCE %	6%	2%	2%	9%	10%	13%	10%	23%	27%	31%	33%	35%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	72.07%	72.07%	72.41%	72.62%	72.62%	72.82%	72.82%	72.82%	72.82%	72.82%	72.82%	72.82%
FIIs	0.20%	0.12%	0.15%	0.08%	0.25%	0.38%	0.33%	0.46%	0.56%	0.90%	1.15%	1.35%
DIIs	0.01%	0.01%	0.01%	0.03%	0.01%	0.11%	0.27%	1.57%	1.77%	2.16%	2.61%	5.45%
Public	27.72%	27.80%	27.43%	27.27%	27.11%	26.70%	26.58%	25.15%	24.85%	24.12%	23.44%	20.40%
No. of Shareholders	22,768	22,821	22,115	20,757	21,360	20,837	20,226	21,088	21,866	22,137	22,232	23,481

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Mirae Asset Multicap Fund	165,269	1.18	22.98	165,269	2025-04-22 16:51:54	0%
Motilal Oswal S&P BSE Healthcare ETF	47	0.07	0.01	47	2025-04-22 17:25:21	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	8.00	8.00	8.00	8.00	8.00
Basic EPS (Rs.)	110.80	53.01	40.90	31.13	24.19
Diluted EPS (Rs.)	110.80	53.01	40.90	31.13	24.19
Cash EPS (Rs.)	123.76	63.33	50.27	40.60	34.15
Book Value[Excl.RevalReserv]/Share (Rs.)	320.80	226.67	186.00	154.66	130.88
Book Value[Incl.RevalReserv]/Share (Rs.)	320.80	226.67	186.00	154.66	130.88
Dividend / Share (Rs.)	24.00	16.00	12.00	9.60	7.20
Revenue From Operations / Share (Rs.)	395.12	351.96	310.09	266.16	235.31
PBDIT / Share (Rs.)	104.20	81.85	65.00	54.03	42.84
PBIT / Share (Rs.)	91.25	71.53	55.62	44.56	32.88
PBT / Share (Rs.)	140.82	71.26	55.44	44.24	32.40
Net Profit / Share (Rs.)	110.80	53.01	40.90	31.13	24.19
PBDIT Margin (%)	26.37	23.25	20.96	20.29	18.20
PBIT Margin (%)	23.09	20.32	17.93	16.74	13.97
PBT Margin (%)	35.63	20.24	17.87	16.62	13.76
Net Profit Margin (%)	28.04	15.06	13.19	11.69	10.27
Return on Networth / Equity (%)	34.53	23.38	21.98	20.12	18.48
Return on Capital Employeed (%)	28.04	30.97	29.05	27.86	24.30
Return On Assets (%)	27.85	17.09	16.12	14.93	13.18
Total Debt / Equity (X)	0.00	0.00	0.00	0.00	0.01
Asset Turnover Ratio (%)	1.12	1.25	1.34	1.36	1.37
Current Ratio (X)	3.88	2.28	2.57	2.58	2.21
Quick Ratio (X)	3.11	1.50	1.64	1.55	1.47
Inventory Turnover Ratio (X)	1.14	1.23	0.96	1.25	1.63
Dividend Payout Ratio (NP) (%)	0.00	22.64	23.47	23.13	0.00
Dividend Payout Ratio (CP) (%)	0.00	18.95	19.10	17.73	0.00
Earning Retention Ratio (%)	0.00	77.36	76.53	76.87	0.00
Cash Earning Retention Ratio (%)	0.00	81.05	80.90	82.27	0.00
Interest Coverage Ratio (X)	277.95	300.80	346.74	171.83	89.67
Interest Coverage Ratio (Post Tax) (X)	163.32	195.80	219.19	100.00	51.63
Enterprise Value (Cr.)	3626.89	2494.10	1093.81	855.55	600.68
EV / Net Operating Revenue (X)	5.55	4.29	2.13	1.94	1.54
EV / EBITDA (X)	21.05	18.43	10.18	9.58	8.48
MarketCap / Net Operating Revenue (X)	5.76	4.35	2.24	2.10	1.65
Retention Ratios (%)	0.00	77.35	76.52	76.86	0.00
Price / BV (X)	7.10	6.75	3.74	3.62	2.96
Price / Net Operating Revenue (X)	5.76	4.35	2.24	2.10	1.65
EarningsYield	0.04	0.03	0.05	0.05	0.06

After reviewing the key financial ratios for RPG Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 8.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 8.00.
For Basic EPS (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
For Diluted EPS (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
For Cash EPS (Rs.), as of Mar 25, the value is 123.76. This value is within the healthy range. It has increased from 63.33 (Mar 24) to 123.76, marking an increase of 60.43.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 320.80. It has increased from 226.67 (Mar 24) to 320.80, marking an increase of 94.13.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 320.80. It has increased from 226.67 (Mar 24) to 320.80, marking an increase of 94.13.
For Dividend / Share (Rs.), as of Mar 25, the value is 24.00. This value exceeds the healthy maximum of 3. It has increased from 16.00 (Mar 24) to 24.00, marking an increase of 8.00.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 395.12. It has increased from 351.96 (Mar 24) to 395.12, marking an increase of 43.16.
For PBDIT / Share (Rs.), as of Mar 25, the value is 104.20. This value is within the healthy range. It has increased from 81.85 (Mar 24) to 104.20, marking an increase of 22.35.
For PBIT / Share (Rs.), as of Mar 25, the value is 91.25. This value is within the healthy range. It has increased from 71.53 (Mar 24) to 91.25, marking an increase of 19.72.
For PBT / Share (Rs.), as of Mar 25, the value is 140.82. This value is within the healthy range. It has increased from 71.26 (Mar 24) to 140.82, marking an increase of 69.56.
For Net Profit / Share (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
For PBDIT Margin (%), as of Mar 25, the value is 26.37. This value is within the healthy range. It has increased from 23.25 (Mar 24) to 26.37, marking an increase of 3.12.
For PBIT Margin (%), as of Mar 25, the value is 23.09. This value exceeds the healthy maximum of 20. It has increased from 20.32 (Mar 24) to 23.09, marking an increase of 2.77.
For PBT Margin (%), as of Mar 25, the value is 35.63. This value is within the healthy range. It has increased from 20.24 (Mar 24) to 35.63, marking an increase of 15.39.
For Net Profit Margin (%), as of Mar 25, the value is 28.04. This value exceeds the healthy maximum of 10. It has increased from 15.06 (Mar 24) to 28.04, marking an increase of 12.98.
For Return on Networth / Equity (%), as of Mar 25, the value is 34.53. This value is within the healthy range. It has increased from 23.38 (Mar 24) to 34.53, marking an increase of 11.15.
For Return on Capital Employeed (%), as of Mar 25, the value is 28.04. This value is within the healthy range. It has decreased from 30.97 (Mar 24) to 28.04, marking a decrease of 2.93.
For Return On Assets (%), as of Mar 25, the value is 27.85. This value is within the healthy range. It has increased from 17.09 (Mar 24) to 27.85, marking an increase of 10.76.
For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Asset Turnover Ratio (%), as of Mar 25, the value is 1.12. It has decreased from 1.25 (Mar 24) to 1.12, marking a decrease of 0.13.
For Current Ratio (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has increased from 2.28 (Mar 24) to 3.88, marking an increase of 1.60.
For Quick Ratio (X), as of Mar 25, the value is 3.11. This value exceeds the healthy maximum of 2. It has increased from 1.50 (Mar 24) to 3.11, marking an increase of 1.61.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 4. It has decreased from 1.23 (Mar 24) to 1.14, marking a decrease of 0.09.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 22.64 (Mar 24) to 0.00, marking a decrease of 22.64.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 18.95 (Mar 24) to 0.00, marking a decrease of 18.95.
For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 77.36 (Mar 24) to 0.00, marking a decrease of 77.36.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 81.05 (Mar 24) to 0.00, marking a decrease of 81.05.
For Interest Coverage Ratio (X), as of Mar 25, the value is 277.95. This value is within the healthy range. It has decreased from 300.80 (Mar 24) to 277.95, marking a decrease of 22.85.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 163.32. This value is within the healthy range. It has decreased from 195.80 (Mar 24) to 163.32, marking a decrease of 32.48.
For Enterprise Value (Cr.), as of Mar 25, the value is 3,626.89. It has increased from 2,494.10 (Mar 24) to 3,626.89, marking an increase of 1,132.79.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.55. This value exceeds the healthy maximum of 3. It has increased from 4.29 (Mar 24) to 5.55, marking an increase of 1.26.
For EV / EBITDA (X), as of Mar 25, the value is 21.05. This value exceeds the healthy maximum of 15. It has increased from 18.43 (Mar 24) to 21.05, marking an increase of 2.62.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.76. This value exceeds the healthy maximum of 3. It has increased from 4.35 (Mar 24) to 5.76, marking an increase of 1.41.
For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 77.35 (Mar 24) to 0.00, marking a decrease of 77.35.
For Price / BV (X), as of Mar 25, the value is 7.10. This value exceeds the healthy maximum of 3. It has increased from 6.75 (Mar 24) to 7.10, marking an increase of 0.35.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.76. This value exceeds the healthy maximum of 3. It has increased from 4.35 (Mar 24) to 5.76, marking an increase of 1.41.
For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of RPG Life Sciences Ltd as of July 4, 2025 is: 2,376.05

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of July 4, 2025, RPG Life Sciences Ltd is Overvalued by 5.71% compared to the current share price 2,520.00

Intrinsic Value of RPG Life Sciences Ltd as of July 4, 2025 is: 3,221.28

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of July 4, 2025, RPG Life Sciences Ltd is Undervalued by 27.83% compared to the current share price 2,520.00

Last 5 Year EPS CAGR: 35.57%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 16.75%, which is a positive sign. The company has higher reserves (212.50 cr) compared to borrowings (18.42 cr), indicating strong financial stability. The company has shown consistent growth in sales (389.83 cr) and profit (61.83 cr) over the years.	The stock has a high average Working Capital Days of 49.67, which may not be favorable. The stock has a high average Cash Conversion Cycle of 80.58, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in RPG Life Sciences Ltd:
1. Net Profit Margin: 28.04%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 28.04% (Industry Average ROCE: 16.64%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 34.53% (Industry Average ROE: 15.18%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 163.32
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 3.11
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 36 (Industry average Stock P/E: 103.53)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

RPG Life Sciences Ltd. is a Public Limited Listed company incorporated on 29/03/2007 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24232MH2007PLC169354 and registration number is 169354. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 653.43 Cr. and Equity Capital is Rs. 13.23 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	RPG House, Mumbai Maharashtra 400030	investorservices@rpgls.com http://www.rpglifesciences.com

Management
Name	Position Held
Mr. Harsh V Goenka	Chairman
Mr. Ashok Nair	Managing Director
Mr. Rajat Bhargava	Non Executive Director
Mr. Yugal Sikri	Non Executive Director
Ms. Vasundhara Patni	Non Executive Director
Mr. Manoj K Maheshwari	Independent Director
Ms. Zahabiya Khorakiwala	Independent Director
Mr. Bhaskar Iyer	Independent Director
Mr. Sachin Nandgaonkar	Independent Director
Ms. Radhika Gupta	Independent Director
Mr. Hiten Kotak	Independent Director
Mr. Anil Matai	Independent Director

FAQ

What is the intrinsic value of RPG Life Sciences Ltd?

RPG Life Sciences Ltd's intrinsic value (as of 04 July 2025) is 2376.05 — 5.71% lower the current market price of 2,520.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,158 Cr. market cap, FY2025-2026 high/low of 2,977/1,540, reserves of 517 Cr, and liabilities of 658 Cr.

What is the Market Cap of RPG Life Sciences Ltd?

The Market Cap of RPG Life Sciences Ltd is 4,158 Cr..

What is the current Stock Price of RPG Life Sciences Ltd as on 04 July 2025?

The current stock price of RPG Life Sciences Ltd as on 04 July 2025 is 2,520.

What is the High / Low of RPG Life Sciences Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of RPG Life Sciences Ltd stocks is ₹2,977/1,540.

What is the Stock P/E of RPG Life Sciences Ltd?

The Stock P/E of RPG Life Sciences Ltd is 36.0.

What is the Book Value of RPG Life Sciences Ltd?

The Book Value of RPG Life Sciences Ltd is 321.

What is the Dividend Yield of RPG Life Sciences Ltd?

The Dividend Yield of RPG Life Sciences Ltd is 0.79 %.

What is the ROCE of RPG Life Sciences Ltd?

The ROCE of RPG Life Sciences Ltd is 32.8 %.

What is the ROE of RPG Life Sciences Ltd?

The ROE of RPG Life Sciences Ltd is 25.5 %.

What is the Face Value of RPG Life Sciences Ltd?

The Face Value of RPG Life Sciences Ltd is 8.00.